• Changmao Biochemical Engineering expects a consolidated net loss attributable to shareholders of RMB 4 million to RMB 6 million for H1 2026.
• The forecast implies a sharp improvement from a RMB 25.79 million net loss a year earlier.
• Performance improvement tied to product mix optimization, capacity expansion, higher revenue, higher gross profit.
• Losses narrowed as demand rose for products from Changmao (Dalian) New Material’s phase II production line.
• Interim results are expected to be released on Aug. 18, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Changmao Biochemical Engineering Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260803-12266925), on August 03, 2026, and is solely responsible for the information contained therein.